Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Cash flows from operating activities:
Net income	$ 74.9	$ 71.7
Noncash items:
Depreciation	7.8	10.3
Amortization	23.5	21.0
Allowance for credit losses	1.7	2.9
Stock-based compensation expense	7.5	6.4
Gain on sale of Kavo treatment unit and instrument business	(6.0)	0.0
Restructuring charges	(1.9)	0.0
Impairment charges	3.9	1.9
Amortization of right-of-use assets	6.4	7.2
Amortization of debt discount and issuance costs	1.0	6.2
Change in trade accounts receivable	(16.2)	(5.1)
Change in inventories	(20.3)	(20.4)
Change in trade accounts payable	(2.5)	(27.6)
Change in prepaid expenses and other assets	(16.8)	(7.9)
Change in accrued expenses and other liabilities	(51.5)	(37.9)
Change in operating lease liabilities	(8.0)	(12.1)
Net cash provided by operating activities	3.5	16.6
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(19.8)	(8.3)
Proceeds from sale of Kavo treatment unit and instrument business	30.0	0.0
All other investing activities, net	(5.1)	2.8
Net cash provided by (used in) investing activities	5.1	(5.5)
Cash flows from financing activities:
Payment of debt issuance and other deferred financing costs	0.0	(0.4)
Proceeds from borrowings	0.3	0.0
Repayment of borrowings	(0.5)	(475.5)
Proceeds from stock option exercises	13.1	5.3
Tax withholding payment related to net settlement of equity awards	(7.6)	(5.2)
All other financing activities	0.0	6.2
Net cash provided by (used in) financing activities	5.3	(469.6)
Effect of exchange rate changes on cash and cash equivalents	(9.2)	10.8
Net change in cash and cash equivalents	4.7	(447.7)
Beginning balance of cash and cash equivalents	1,073.6	888.9
Ending balance of cash and cash equivalents	1,078.3	441.2
Supplemental data:
Cash paid for interest	2.8	10.5
Cash paid for taxes	14.1	5.7
ROU assets obtained in exchange for operating lease obligations	$ 7.1	$ 2.6